Prosecution Insights
Prosecution Insights
Technology area: Biotechnology & Pharmaceuticals
3 pending office actions • 2 art units • 3 examiners • 0 of 3 (0%) have an AI response strategy ready • 2 patents granted in the last 365 days
Qure Biotechnology (Shanghai) Co. Ltd. manages 3 pending office actions within the Biotechnology & Pharmaceuticals technology area. These actions are distributed across 2 distinct art units, suggesting that the company's biological innovations span multiple specialized examination groups. The involvement of 3 distinct examiners for these 3 actions means that every pending matter is being reviewed by a different individual. This diversity of examiners can provide the company with a range of feedback on their patent applications.
The busiest examiner, HOPKINS, SAMANTHA LAKE, is responsible for 1 busiest examiner pending action. Since there are 3 pending office actions in total, the workload is distributed among the 3 distinct examiners. This distribution allows the company to receive feedback from multiple perspectives within the 2 distinct art units, potentially providing a broader view of how the patent office perceives their biotechnology claims. Practitioners should be prepared to manage different examiner styles across the art units involved.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §103 only | 1 (33%) |
| Multi-statute (no §101) | 2 (67%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| HOPKINS, SAMANTHA LAKE | 1 | 60.4% | +62.3% |
| HALVORSON, MARK | 1 | 47.9% | +20.7% |
| LU, CHENG | 1 | 54.1% | +64.1% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 2 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18566817 | ANTI-CD3 ANTIBODY VARIANT, FUSION PROTEIN, AND APPLICATION | HOPKINS, SAMANTHA LAKE | — |
| 18256679 | BISPECIFIC ANTIBODY AND APPLICATION THEREOF | HALVORSON, MARK | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 3 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18566817 | ANTI-CD3 ANTIBODY VARIANT, FUSION PROTEIN, AND APPLICATION | HOPKINS, SAMANTHA LAKE | — |
| 18256679 | BISPECIFIC ANTIBODY AND APPLICATION THEREOF | HALVORSON, MARK | — |
| 18256023 | TRIFUNCTIONAL FUSION PROTEIN CONTAINING TUMOR-ASSOCIATED ANTIGEN (TAA) ANTIBODY AND APPLICATION THEREOF | LU, CHENG | — |
| Art Unit | Apps |
|---|---|
| 1646 | 1 |
| 1642 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18566817 | ANTI-CD3 ANTIBODY VARIANT, FUSION PROTEIN, AND APPLICATION | HOPKINS, SAMANTHA LAKE | — | §102§103§112 | Non-Final OA | — | Pending | Dec 04, 2023 |
| 18256679 | BISPECIFIC ANTIBODY AND APPLICATION THEREOF | HALVORSON, MARK | 1646 | §103§112 | Non-Final OA | — | Pending | Jun 09, 2023 |
| 18256023 | TRIFUNCTIONAL FUSION PROTEIN CONTAINING TUMOR-ASSOCIATED ANTIGEN (TAA) ANTIBODY AND APPLICATION THEREOF | LU, CHENG | 1642 | §103 | Final Rejection | — | Pending | Jun 05, 2023 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial